Lördag 26 April | 16:28:54 Europe / Stockholm

Svenska | English

Oculis Holding

Beskrivning

Land	Schweiz
Lista	Mid Cap Iceland
Sektor	Hälsovård
Industri	Bioteknik

Oculis Holding är specialiserade inom bioteknik. Bolaget bedriver forskning och utveckling inom topikala behandlingar för ögonsjukdomar. Exempel på specialistområden inkluderar diabetiskt makulaödem, bahandlingar för torra ögon och akut optisk neurit. Störst verksamhet återfinns inom Europa, där forskning bedrivs i egen regi men även via samarbetspartners. Bolaget har sitt huvudkontor i Zug, Schweiz.

Filter

År

Typ

Språk

Rensa

2025-04-25 22:00:00 Oculis Updates Share Capital 2290,00 ISK | +0,44%

2025-04-17 11:00:00 Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award

2025-04-15 10:00:00 Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets 2280,00 ISK | +5,56%

2025-04-10 14:00:00 Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema 2040,00 ISK | +9,68%

2025-04-10 10:00:00 Oculis lýkur innritun sjúklinga í báðar DIAMOND fasa 3 rannsóknirnar á OCS-01 sem meðferð við sjónhimnubjúg af völdum sykursýki 2040,00 ISK | +9,68%

2025-04-10 10:00:00 Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema 2040,00 ISK | +9,68%

2025-04-09 23:00:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 1860,00 ISK | -7,46%

2025-04-01 10:00:00 Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond 2480,00 ISK | 0,00%

2025-03-20 23:01:00 Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities 2580,00 ISK | +3,20%

2025-03-14 21:31:47 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2500,00 ISK | -0,40%

2025-03-11 21:30:00 Oculis birtir uppgjör fyrir fjórða ársfjórðung og árið 2024 og kynnir áfanga í rekstri félagsins 2440,00 ISK | -2,40%

2025-03-11 21:30:00 Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update 2440,00 ISK | -2,40%

2025-03-05 10:00:00 Oculis to Present at Upcoming March Investor Conference 2620,00 ISK | +3,15%

2025-03-03 09:18:33 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2740,00 ISK | -0,72%

2025-02-14 01:40:48 Oculis greinir frá umframeftirspurn og öðrum niðurstöðum 100 milljón USD útboðs á almennum hlutum 3020,00 ISK | -1,31%

2025-02-14 01:40:48 Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares 3020,00 ISK | -1,31%

2025-02-14 01:39:36 Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares 3020,00 ISK | -1,31%

2025-02-08 00:35:06 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated 3180,00 ISK | +0,63%

2025-01-31 22:00:00 Oculis updates share capital for its existing at-the-market offering program 3260,00 ISK | +3,82%

2025-01-21 22:00:00 Oculis Publishes Notification of Major Changes in Voting Rights 3200,00 ISK | -1,23%

2025-01-20 23:00:00 Oculis Publishes Notification of Major Changes in Voting Rights 3240,00 ISK | +3,18%

2025-01-06 09:53:25 Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy 2480,00 ISK | +0,40%

2025-01-06 09:47:00 Oculis tilkynnir um jákvæðar niðurstöður úr fasa 2 ACUITY rannsóknar á OCS-05 við sjóntaugabólgu; aðalviðmiði um öryggi náð auk lykilviðmiða um virkni sem opnar á þróun sem mögulegt fyrsta lyf sinnar tegundar á sviði taugaverndandi meðferða 2480,00 ISK | +0,40%

2025-01-06 09:47:00 Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy 2480,00 ISK | +0,40%

2025-01-04 00:48:20 Oculis Publishes Notification of Major Changes in Voting Rights 2470,00 ISK | +2,07%

2024-12-06 22:00:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2140,00 ISK | 0,00%

2024-11-29 10:00:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated 2220,00 ISK | -0,89%

2024-11-27 10:15:47 Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities 2220,00 ISK | +4,72%

2024-11-13 10:00:00 Oculis to Present at the Stifel 2024 Healthcare Conference 2100,00 ISK | -2,78%

2024-11-07 10:00:00 Oculis Reports Q3 2024 Financial Results and Provides Company Updates 2330,00 ISK | -4,51%

2024-11-07 10:00:00 Oculis birtir uppgjör fyrir þriðja ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins 2330,00 ISK | -4,51%

2024-11-07 10:00:00 Oculis Reports Q3 2024 Financial Results and Provides Company Updates 2330,00 ISK | -4,51%

2024-10-21 19:04:57 Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees 2120,00 ISK | +9,84%

2024-10-21 10:00:00 Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees 2120,00 ISK | +9,84%

2024-10-15 10:00:00 Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024 1960,00 ISK | -1,01%

2024-10-02 10:00:00 Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer 1670,00 ISK | +1,83%

2024-09-19 19:00:00 Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award 1630,00 ISK | -0,61%

2024-08-29 10:00:00 Oculis to Present at Upcoming September Investor Conferences 1680,00 ISK | 0,00%

2024-08-27 22:00:00 Oculis Publishes Consolidated Q2 Financial Statements and MD&A 1650,00 ISK | +1,85%

2024-08-27 10:00:00 Oculis birtir uppgjör fyrir annan ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins 1650,00 ISK | +1,85%

2024-08-27 10:00:00 Oculis Reports Q2 Financial Results and Provides Recent Company Update 1650,00 ISK | +1,85%

2024-08-27 10:00:00 Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update 1650,00 ISK | +1,85%

2024-08-15 14:00:00 Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer 1640,00 ISK | 0,00%

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Oculis Holding

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden